Please assess the completion status of the following clinical trial:

Trial Title: Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with confirmed diagnosis of advanced, non resectable and/or metastatic solid tumours, who have failed conventional treatment, and for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment~2. Age \> or = 18 years~3. European Cooperative Oncology Group performance status \< or = 2~4. Written informed consent in accordance with International Conference on Harmonization -Good Clinical Practice (ICH-GCP) and local legislation~5. Recovery from Common Terminology Criteria for Adverse Events grade 2-4 therapy-related toxicities from previous systemic anti-cancer therapies or radiotherapy (except alopecia)~Exclusion criteria:~1. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the trial~2. Known hypersensitivity to the trial drugs or their excipients~3. Treatment with any other investigational drug or participation in any other interventional trial within 28 days before first administration of trial drug (BIBF 1120) or concomitantly with this trial~4. Systemic anti-cancer therapy or radiotherapy within 28 days before start of therapy or concomitantly with this trial. The restriction does not apply to steroids and bisphosphonates~5. Active infectious disease infection or HIV I/II~6. Other malignancy currently requiring another anti-cancer therapy~7. Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the past 6 months~8. Known inherited predisposition to bleeding or thrombosis~9. Radiographic evidence of cavitary or necrotic tumours~10. History of clinically significant haemoptysis within the past 3 months~11. Centrally located tumours with radiographic evidence (Computed Tomography or Magnetic Resonance Imaging) of local invasion of major blood vessels~12. Absolute Neutrophil Count (ANC) less than 1.5 x 1000000000/L~13. Platelets Count (PLT) less than 100 x 1000000000/L~14. Total bilirubin \> upper limit of normal (ULN)~15. Alaninaminotransferase (ALT) and/or Aspartateaminotransferase (AST) \>= 1.5 x ULN (in case of liver metastases: ALT and AST \>= 2.5 x ULN)~16. Serum creatinine \> 1.5 mg/dl~17. Major injuries and/or surgery or bone fracture within 28 days before first administration of trial drug (BIBF 1120), or planned surgical procedures during the trial period~18. Known history of clinically relevant QT prolongation (e.g. long QT syndrome)~19. History of severe haemorrhagic or thromboembolic event in the past 6 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis)~20. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid \< or = 325mg per day)~21. Active alcohol or drug abuse~22. Women and men who are sexually active and unwilling to use a medically acceptable method of contraception during the trial~23. Pregnancy or breast-feeding~24. Patients unable to comply with the protocol~25. Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBF 1120 and BI 6727 (Type: EXPERIMENTAL): Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120

Based on this trial design, predict the completion outcome and termination type (if applicable).